# A Clinical Trial to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin

> **NCT02392130** · PHASE1 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 40 (actual)

## Conditions studied

- Skin Tissue Diseases
- Connective Tissue Diseases

## Interventions

- **DRUG:** Clobetasol propionate 0.05% ointment
- **DRUG:** LEO 130852A gel 1%
- **DRUG:** LEO 130852A placebo gel

## Key facts

- **NCT ID:** NCT02392130
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02392130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02392130, "A Clinical Trial to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02392130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*